Close menu

Combining BIOCORP’s pen injector add-on Mallya® with AARDEX® Group’s Software to improve adherence to medication in a Hybrid Phase IV Diabetes Study


Issoire (France), July 21st, 2022, 6:00 pm CET – BIOCORP (FR0012788065 – ALCOR / Eligible PEA-PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, and Belgium-based AARDEX GROUP, the leader in tools for measuring and managing adherence to medication in clinical trials are proud to announce one of their first major joint initiatives that will come live in the upcoming months. Both companies today announced they have been recruited by Trials@Home to take part in a Phase IV study called RADIAL. Trials@Home is a center of excellence for Decentralized Clinical Trials (DCTs), whose members include notably Sanofi, J&J, Pfizer.


Discover the press release

More information